Gene D. Arcy

FDA investigator · also recorded as Se Gene Arcy

Appears on 16 documents from 2003 to 2025, most often at sites in California. Most often cites production record review (21 CFR 211.192).

16
Documents on file
4.8
Observations per 483
2003
First seen
2025
Most recent

What they cite most

From 75 observations

Activity by year

2003: 1, 2016: 1, 2017: 2, 2018: 1, 2019: 2, 2020: 1, 2021: 1, 2022: 1, 2023: 3, 2024: 2, 2025: 1

Where

California 4 · North Carolina 3 · Michigan 2 · Australia 1 · Belgium 1 · Massachusetts 1

Is Gene D. Arcy coming to your site?

Our team writes custom reports before an inspection: what this investigator cites most, how they write it up, and how your site's history compares, in one brief you can circulate.

Ask about any investigator in Claude or ChatGPT with the AI connector.

Inspection history

16 documents, newest first
FirmOpen
483 Baxalta US IncSep 18, 2025 · Thou sand Oak s, California
483 FinVector OyMay 28, 2024
483 MedImmune UK LimitedMar 15, 2024 · Liverpool, United Kingdom
483 Biogen U.S. CorporationOct 17, 2023 · Morrisville, North Carolina
483 Wyeth BioPharma Division of Wyeth Pharmaceuticals LLCSep 19, 2023 · Andover, Massachusetts
483 Pharmacia & Upjohn Company LLCJun 16, 2023 · Kalamazoo, Michigan
483 Grifols Therapeutics LLCMay 6, 2022 · Clayton, North Carolina

About this profile

What does Gene D. Arcy inspect?

Gene D. Arcy appears on 16 documents on file covering 14 sites, most often in California.

What do they cite most often?

21 CFR 211.192 (production record review), followed by 21 CFR 211.100 and 21 CFR 211.110.

Can I read the observations?

Each document page previews the opening words of every observation. The full documents are available to buy, one at a time or together.

How current is this profile?

The most recent document on file for Gene D. Arcy is dated Sep 18, 2025.